Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets Versus Amoxicillin-Clavulanate for the Treatment of Acute Bacterial Sinusitis

Completed · Phase 3

Conditions studied: Acute Bacterial Sinusitis (ABS)

In brief

To compare the safety/tolerability and efficacy of a 14-day course of clarithromycin extended-release tablets (2 x 500 mg QD) with that of a 14-day course of amoxicillin-clavulanate tablets (875/125 mg BID) for the treatment of ambulatory subjects with Acute Bacterial Sinusitis (ABS).

Key facts

Study ID

NCT00644553

Run by

Abbott

People needed

437

Starts

2003-05-01

Last updated by the study team

2008-03-27

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The female must be non-lactating and at no risk for pregnancy.
• Subject must have a diagnosis of ABS. The diagnosis must be based on the following:
• A sinus radiograph (Water's view) or CT scan with evidence of maxillary opacification or
• Air/fluid levels purulent discharge from the nose
• At least two of the following additional signs and symptoms lasting longer than seven days prior to and no longer than 28 days before Evaluation 1.
• A pre-treatment sample from a sinus puncture or
• Middle meatus endoscopy must be obtained for bacterial aerobic culture
• Susceptibility testing (applicable only for selected investigative sites).
• Subject must be a suitable candidate for oral antibiotic therapy and able to swallow tablets intact.

You may not qualify if…

• A medical history of hypersensitivity or allergic reactions to clarithromycin, erythromycin, amoxicillin/clavulanate, any penicillin or any of the macrolide antibiotics.
• History of amoxicillin-clavulanate associated cholestatic jaundicehepatic dysfunction.
• Females who are pregnant or lactating.
• Subject has either of the following:
• Chronic sinusitis (signs and symptoms lasting longer than 28 days immediately prior to Evaluation 1)
• Significant anatomical abnormalities of the sinuses any other infection or
• Condition which necessitates use of a concomitant systemic antibiotic.
• Evidence of uncontrolled clinically significant cardiovascular, pulmonary, metabolic, gastrointestinal, neurological, psychiatric or endocrine disease, malignancy, or other abnormality (other than the disease being studied).
• Any underlying condition/disease, that would be likely to interfere with the completion of the course of study drug therapy or follow-up.
• Known significant renal or hepatic impairment (or disease).
• Subject who has taken: a systemic antibiotic within 2 weeks before study drug administration or a long-acting injectable antibiotic (e.g., penicillin G benzathine) within 4 weeks before study drug administration.
• Immunocompromised subjects (e.g., neutropenic subjects).
• Subjects with known HIV infection.
• Treatment with any other investigational drug within 4 weeks prior to study drug administration.

Where it is running

• Study site — Phoenix, Arizona, United States
• Study site — Clovis, California, United States
• Study site — La Jolla, California, United States
• Study site — San Luis Obispo, California, United States
• Study site — Coeur d'Alene, Idaho, United States
• Study site — Charlotte, North Carolina, United States
• Study site — Columbus, Ohio, United States
• Study site — Eugene, Oregon, United States
• Study site — Johnson City, Tennessee, United States
• Study site — San Antonio, Texas, United States
• Study site — Spokane, Washington, United States
• Study site — Kitchener, Ontario, Canada
• Study site — Toronto, Ontario, Canada
• Study site — Sherbrooke, Quebec, Canada
• Study site — Saskatoon, Saskatchewan, Canada
• Study site — Athens, Greece
• Study site — Athens, Greece
• Study site — Pátrai, Greece
• Study site — Piraeus, Greece
• Study site — Thessaloniki, Greece
• Study site — Thessaloniki, Greece
• Study site — Budapest, Hungary
• Study site — Budapest, Hungary
• Study site — Budapest, Hungary
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.